128 related articles for article (PubMed ID: 35760938)
61. COVID-19 outcomes in patients with and without autoimmune rheumatic diseases: A multicenter comparative study.
Abdulnaby NK; Gamal SM; Alkemary A; Abdo M; Sabry IM; Belita MI; Mohamed SS
Int J Rheum Dis; 2023 May; 26(5):870-877. PubMed ID: 36929695
[TBL] [Abstract][Full Text] [Related]
62. COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): a systematic review and meta-analysis.
Shin JI; Kim SE; Lee MH; Kim MS; Lee SW; Park S; Shin YH; Yang JW; Song JM; Moon SY; Kim SY; Park Y; Suh DI; Yang JM; Cho SH; Jin HY; Hong SH; Won HH; Kronbichler A; Koyanagi A; Jacob L; Hwang J; Tizaoui K; Lee KH; Kim JH; Yon DK; Smith L
Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3760-3770. PubMed ID: 35647859
[TBL] [Abstract][Full Text] [Related]
63. Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveys.
Jagtap K; Naveen R; Day J; Sen P; Vaidya B; Nune A; Nikiphorou E; Tan AL; Agarwal V; Saha S; Shinjo SK; Ziade N; Joshi M; Velikova T; Milchert M; Parodis I; Edgar Gracia-Ramos A; Cavagna L; Kuwana M; Knitza J; Makol A; Patel A; Pauling JD; Wincup C; Barman B; Zamora Tehozol EA; Rojas Serrano J; García-De La Torre I; Colunga-Pedraza IJ; Merayo-Chalico J; Chibuzo OC; Katchamart W; Goo PA; Shumnalieva R; Chen YM; Hoff LS; El Kibbi L; Halabi H; Sazliyana Shaharir S; Hasan ATMT; Dey D; Gutiérrez CET; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Chatterjee T; Saavedra MA; Distler O; ; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Rheumatology (Oxford); 2023 Dec; 62(12):3838-3848. PubMed ID: 36961331
[TBL] [Abstract][Full Text] [Related]
64. Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey.
Ahmed S; Gupta L; Kuwana M; Pauling JD; Day J; Ravichandran N; Joshi M; Parodis I; Sen P; Jagtap K; Nikiphorou E; Saha S; Agarwal V; Chatterjee T; Lilleker JB; Kardes S; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Tan AL; Nune A; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Distler O; Wibowo SAK; ; Chinoy H; Aggarwal R; Agarwal V; Makol A
Rheumatol Int; 2024 Jan; 44(1):89-97. PubMed ID: 37668836
[TBL] [Abstract][Full Text] [Related]
65. Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases.
Yap RXL; Lai YW; Wei C; Ng JJW; Xu D; Feng S; Mu R; Thong BY; Xu C
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543908
[TBL] [Abstract][Full Text] [Related]
66. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group.
Panchawagh S; Ravichandran N; Barman B; Nune A; Javaid M; Gracia-Ramos AE; Day J; Joshi M; Kuwana M; Saha S; Pande AR; Caballero-Uribe CV; Velikova T; Parodis I; Knitza J; Kadam E; Tan AL; Shinjo SK; Boro H; ; Aggarwal R; Agarwal V; Chatterjee T; Gupta L
Rheumatol Int; 2024 Jan; 44(1):73-80. PubMed ID: 38060005
[TBL] [Abstract][Full Text] [Related]
67. Characteristics and risk factors of COVID-19 breakthrough infections in Idiopathic Inflammatory Myopathies: Results from the COVAD study.
Hoff LS; Naveen R; Sen P; Day J; Joshi M; Nune A; Nikiphorou E; Saha S; Tan AL; Shinjo SK; Ziade N; Velikova T; Milchert M; Jagtap K; Parodis I; Edgar Gracia-Ramos A; Cavagna L; Kuwana M; Knitza J; Chen YM; Makol A; Agarwal V; Patel A; Pauling JD; Wincup C; Barman B; Zamora Tehozol EA; Rojas Serrano J; García-De La Torre I; Colunga-Pedraza IJ; Merayo-Chalico J; Chibuzo OC; Katchamart W; Akarawatcharangura Goo P; Shumnalieva R; El Kibbi L; Halabi H; Vaidya B; Shaharir SS; Hasan ATMT; Dey D; Toro Gutiérrez CE; Caballero-Uribe CV; Lilleker JB; Salim B; Gheita T; Chatterjee T; Distler O; Saavedra MA; ; Chinoy H; Agarwal V; Aggarwal R; Gupta L
Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38430474
[TBL] [Abstract][Full Text] [Related]
68. Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset.
Chebbi P; Shobha V; Rao VK; Haridas V; Janardana R; Pinto B; Kumar S; Patil A; Tekkatte R; Salanke M; Mahendranath KM
BMC Rheumatol; 2023 Jul; 7(1):22. PubMed ID: 37496101
[TBL] [Abstract][Full Text] [Related]
69. COVID-19 Infection In Patients With Autoimmune Rheumatic Diseases: Patient's Perspective And Descriptive Analysis From A Lower-Middle-Income Country.
Riaz M; Ishaq S; ; Jibril H; Zafar Mahmood SB; Riaz M
J Pak Med Assoc; 2023 Oct; 73(10):2059-2061. PubMed ID: 37876070
[TBL] [Abstract][Full Text] [Related]
70. CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.
Chevalier K; Genin M; Jean TP; Avouac J; Flipo RM; Georgin-Lavialle S; El Mahou S; Pertuiset E; Pham T; Servettaz A; Marotte H; Domont F; Chazerain P; Devaux M; Mekinian A; Sellam J; Fautrel B; Rouzaud D; Ebstein E; Costedoat-Chalumeau N; Richez C; Hachulla E; Mariette X; Seror R
Front Med (Lausanne); 2023; 10():1152587. PubMed ID: 37035330
[TBL] [Abstract][Full Text] [Related]
71. Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases.
Kato Y; Morita T; Kumanogoh A
Inflamm Regen; 2023 Jan; 43(1):1. PubMed ID: 36609472
[TBL] [Abstract][Full Text] [Related]
72. Comparison of Risk Factors During First and Second Wave of COVID-19 in Patients with Autoimmune Rheumatic Diseases (AIRD): Results from KRACC Subset.
Jain V; Shobha V; Kumar S; Janardana R; Selvam S
Mediterr J Rheumatol; 2023 Sep; 34(3):342-348. PubMed ID: 37941863
[TBL] [Abstract][Full Text] [Related]
73. COVID-19 mRNA vaccine booster in patients with autoimmune rheumatic diseases.
Cardelli C; Caruso T; Tani C; Pratesi F; Talarico R; Di Cianni F; Italiano N; Laurino E; Moretti M; Cascarano G; Diomedi M; Gualtieri L; D'Urzo R; Migliorini P; Mosca M
Rheumatology (Oxford); 2022 Nov; 61(11):e328-e330. PubMed ID: 35608304
[No Abstract] [Full Text] [Related]
74. Vaccines in adults with autoimmune inflammatory rheumatic disease: What are the knowledge and attitudes of physicians?
Badak SÖ
Arch Rheumatol; 2022 Sep; 37(3):456-465. PubMed ID: 36589615
[TBL] [Abstract][Full Text] [Related]
75. COVID-19 and autoimmune phenomena: Vitiligo after Astrazeneca vaccine.
López Riquelme I; Fernández Ballesteros MD; Serrano Ordoñez A; Godoy Díaz DJ
Dermatol Ther; 2022 Jul; 35(7):e15502. PubMed ID: 35393710
[No Abstract] [Full Text] [Related]
76. Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: two cases, infectious and inflammatory.
Yoon JP; Jung YS; Kim DH
JSES Rev Rep Tech; 2022 Aug; 2(3):376-379. PubMed ID: 35571584
[No Abstract] [Full Text] [Related]
77. Response to: Factors Associated With COVID-19 Breakthrough Infections: Correspondence.
Rivelli A; Fitzpatrick V; Copeland K; Richards J
J Occup Environ Med; 2022 Nov; 64(11):e794. PubMed ID: 35902338
[No Abstract] [Full Text] [Related]
78. Factors Associated With COVID-19 Breakthrough Infections: Correspondence.
Mungmunpuntipantip R; Wiwanitkit V
J Occup Environ Med; 2022 Nov; 64(11):e793. PubMed ID: 35902329
[No Abstract] [Full Text] [Related]
79. Suspending methotrexate for 2 weeks after COVID-19 vaccination.
Coates LC; Abhishek A
Lancet Rheumatol; 2022 Nov; 4(11):e740-e741. PubMed ID: 36118533
[No Abstract] [Full Text] [Related]
80. Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis.
Widhani A; Hasibuan AS; Rismawati R; Maria S; Koesnoe S; Hermanadi MI; Ophinni Y; Yamada C; Harimurti K; Sari ANL; Yunihastuti E; Djauzi S
Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
